Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
AVTX insider filed a Form 144 reporting a proposed sale of 16,915 restricted stock units. The filing lists Morgan Stanley Smith Barney LLC as the broker. It also reports executed 10b5-1 sales of 7,979 shares on 04/01/2026 for $133,770.33 and 7,980 shares on 04/02/2026 for $136,822.69.
Avalo Therapeutics, Inc. entered into a Milestone Buyout Option Agreement and amendment tied to its March 2024 acquisition of AlmataBio, Inc. The original $15 million contingent milestone payment, due upon dosing the first patient in a Phase 3 trial, has been restructured.
Avalo will pay $2.25 million to the former AlmataBio securityholders within five business days of April 26, 2026 and gains an option, exercisable within 90 days, to pay an additional $5.125 million in cash, common stock, or both, in full satisfaction of the milestone. If Avalo does not exercise this option, it would instead owe $12.75 million in cash or stock upon achievement of the Phase 3 dosing milestone.
Avalo Therapeutics, Inc. is holding a virtual 2026 Annual Meeting of Stockholders on June 2, 2026, for holders of 26,714,337 common shares as of April 6, 2026. Stockholders will vote on electing seven directors, approving a Second Amended and Restated 2016 Employee Stock Purchase Plan, and ratifying Ernst & Young LLP as independent auditor for 2026.
The updated employee stock purchase plan would keep 961,608 shares available and add an annual “evergreen” increase from 2027 through 2036, capped at the lesser of 1% of specified equity outstanding or 4,000,000 shares per year. The proxy also outlines Avalo’s board independence, committee structure, director compensation, and governance policies.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, Doyle exercised options to acquire 3,970 shares of common stock at $12.65 per share, then sold all 3,970 shares in open-market trades at an average price of about $18.01, with individual trades ranging from $18.00 to $18.10. Following the sale, Doyle directly held 3,622 shares of common stock and 210,530 stock options. The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, and that the underlying option vests over four years, with 25% vesting on July 15, 2025 and the remainder in equal monthly installments over the next three years.
AVTX filed a Form 144 disclosing the proposed sale of 65,800 shares of common stock on 04/06/2026 arising from an exercise of stock options for cash. The filing also lists recent Rule 10b5-1 sales by Mittie Doyle: 25,492 shares on 03/16/2026 and 679 shares on 04/01/2026.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported open-market sales of Avalo common stock in early April 2026. He sold a total of 15,959 shares over two days at prices around $15.858 to $17.5674 per share, in multiple transactions.
The filing notes these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025. Following the transactions, Sullivan directly holds 17,338 shares of Avalo Therapeutics common stock.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an option exercise and same-day share sale in Avalo Therapeutics, Inc. common stock. Mittie exercised stock options to acquire 679 shares of common stock at $8.04 per share, then sold 679 shares at $16.00 per share in an open-market transaction.
After these transactions, Mittie directly holds 3,622 shares of common stock and 148,329 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the timing was set in advance rather than decided on the trade date.
Avalo Therapeutics director Rita Jain received a new stock option grant. On March 31, 2026, she was granted options to acquire 1,339 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The options were granted fully vested and expire on March 31, 2036. Following this grant, she holds 1,339 options directly as reported in this filing.